Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission – a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry
Pleyer, L; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattesberger, M; Tinchon, C; Hartmann, B; Petzer, A; Petricevic, B; Schmitt, CA; Vallet, S; Geissler, K; Sperr, WR; Leisch, M; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Angermann, H; Drost, M; Larcher-Senn, J; Greil, R BLOOD. 2021; 138:
SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Tam, CS; Giannopoulos, K; Jurczak, W; Simkovic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, H; Ciepluch, H; Greil, R; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Brown, JR; Kahl, BS; Ghia, P; Tian, T; Marimpietri, C; Paik, JC; Cohen, A; Huang, J; Robak, T; Hillmen, P BLOOD. 2021; 138:
The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry – a Prospective Cohort Study By the AGMT Study Group
Pleyer, L; Heibl, S; Tinchon, C; Vallet, S; Petricevic, B; Leisch, M; Egle, A; Senn, TM; Grochtdreis, T; Greil, R; Stauder, R BLOOD. 2021; 138:
Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders – Results from the Aachen Telomeropathy Registry
Beier, F; Tometten, M; Kirschner, M; Halfmeyer, I; Vieri, M; Kricheldorf, K; Maurer, A; Roeth, A; Platzbecker, U; Radsak, MP; Schafhausen, P; Corbacioglu, S; Hoechsmann, B; Wilk, CM; Hinze, C; Chromik, J; Egle, A; Heuser, M; Kreuter, M; Kurth, I; Koschmieder, S; Panse, J; Meyer, R; Isfort, S; Brummendorf, TH BLOOD. 2021; 138:
Lack of Bmf Facilitates the Selection of Highly Responsive B-Cell Receptor Clones in Chronic Lymphocytic Leukemia
Maeding, N; Asslaber, D; Zaborsky, N; Villunger, A; Greil, R; Egle, A BLOOD. 2021; 138:
Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)
Manrique, I; Greil, R; Andel, J; Sormann, S; Hartmann, BL; Podar, K; Egle, A; Petzer, A; Zojer, N; Gunsilius, E; Ruckser, R; Bozic, B; Schmitt, CA; Machherndl-Spandl, S; Agis, H; Schreder, M; Wang, SY; Willenbacher, W; Krauth, MT; Tinchon, C; Fillitz, M; Melchardt, T; Knop, S; Paiva, B; Ludwig, H BLOOD. 2021; 138:
Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkinxxxs Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial
Sureda, A; Pilar Gonzalez, A; Nunez, J; Briones, J; De la Cruz, F; Domenech Eva, D; Maria Hernandez, F; JoseTerol, M; Amutio, E; Cordoba, R; Martinez, C; Moreno, M; Izquierdo, AR; Del Campo, R; Greil, R; Romero, S; Garcia-Sanz, R BLOOD. 2021; 138:
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Bishop, MR; Dickinson, M; Purtill, D; Barba, P; Santoro, A; Hamad, N; Kato, K; Sureda, A; Greil, R; Thieblemont, C; Morschhauser, F; Janz, M; Flinn, IW; Rabitsch, W; Kwong, YL; Kersten, MJ; Minnema, MC; Holte, H; Chan, EHL; Martinez-Lopez, J; Mueller, AMS; Maziarz, RT; McGuirk, JP; Bachy, E; Le Gouill, S; Dreyling, M; Harigae, H; Bond, DA; Andreadis, C; McSweeney, PA; Kharfan-Dabaja, MA; Newsome, S; Degtyarev, E; Del Corral, C; Andreola, G; Masood, A; Schuster, SJ; Jaeger, U; Borchmann, P; Westin, JR BLOOD. 2021; 138:
Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
Greil, R; Chau, I; Doki, Y; Ajani, JA; Xu, J; Wyrwicz, L; Motoyama, S; Ogata, T; Kawakami, H; Hsu, CH; Adenis, A; el Hajbi, F; Di Bartolomeo, M; Braghiroli, MI; Holtved, E; Xynos, I; Liu, X; Lei, M; Kondo, K; Kato, K; Kitagawa, Y ONCOL RES TREAT. 2021; 44: 81-82.
Phase Ib study of the anti-TGF-beta monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.
Bauer, TM; Lin, CC; Greil, R; Goebeler, ME; Huetter-Kroenke, ML; Garrido-Laguna, I; Santoro, A; Perotti, A; Spreafico, A; Yau, T; Joerger, M; Cremasco, V; Dostalek, M; Pelletier, M; Barys, L; Lu, D; Katsanou, V; Fabre, C; Doi, T J CLIN ONCOL. 2021; 39(15):
